DAX
Dow
Nikkei
Gold
Euro
Öl
Bitcoin
App
Blog
Hilfe
onvista bank
Anmelden
Börse & Kurse
News & Analysen
my onvista
Premium
Einstellungen
onvista bank
News
Analysen
Podcasts
Videos
Forum
News-Übersicht
News-Finder
onvista-Redaktion
onvista-Autoren
Agenturmeldungen
Marktberichte
Trading-Chance
Directors' Dealings
Finanzkalender
Börse & Kurse
Aktien
Aktienkurse
Aktien-Finder
Top/Flop
Meistgesuchte Aktien
Aktien aller Länder
Basiswissen Aktien
Indizes
Indizes-Übersicht
Index-Finder
Derivate
Derivate-Übersicht
Derivate-Finder
Optionsschein-Rechner
Neuemissionen
Derivate-Wissen
Derivate-News
Fonds
Fonds-Übersicht
Fonds-Finder
Top/Flop
Performance-Rangliste
Neuemissionen
Fonds-Vergleich
KVGs
Meistgesuchte Fonds
ETF
ETF-Übersicht
ETF-Finder
Top/Flop
Neuemissionen
ETF-Vergleich
Meistgesuchte ETFs
Basiswissen ETF
Anleihen
Anleihen
Anleihen-Finder
Vergleich
Meistgesuchte Anleihen
Devisen
Devisen-Übersicht
Devisen-Finder
Cross-Rates
Währungsrechner
Kryptowährungen
Kryptowährungen
Die größten Kryptowährungen
Krypto-Wissen
Rohstoffe
Futures
Realtime Kurse
DAX Realtime
TecDAX Realtime
MDAX Realtime
SDAX Realtime
EuroStoxx Realtime
Dow Jones Realtime
US Tech 100 Realtime
S&P 500 Realtime
Nikkei Realtime
Anlagethemen
Ratgeber
Top-Werte
Top-Werte
Meistgesuchte Aktien
Meistgesuchte Fonds
Meistgesuchte ETFs
Meistgesuchte Anleihen
Meistgesuchte Derivate
News & Analysen
News
News-Übersicht
News-Finder
onvista-Redaktion
onvista-Autoren
Agenturmeldungen
Marktberichte
Trading-Chance
Directors' Dealings
Finanzkalender
Analysen
Podcasts
Zins & Zaster
Börse & Investments
Videos
Alle Videos
Mahlzeit
Chartzeit
Forum
Forum-Übersicht
Suche
Beitrag verfassen
Boardmail
Meistgelesene Beiträge
Signatur/Avatar
Nutzungsbedingungen
my onvista
Übersicht
Portfolio
Musterdepot
Watchlist
Wertpapierhandel
Handelssysteme
Handelssystem Germany 100
Handelssystem US 100
Chance Germany 40
Chance Germany 100
Invest Germany 40
Invest Germany 100
Experten
Experten-Musterdepot
Experten-Watchlist
Analysen
Premium
Preise
Basic
Plus
Pro
Handelssysteme
Einstellungen
onvista bank
Anmelden
News & Analysen
News
News zu Abionyx Pharma
Werbung ausblenden
News zu Abionyx Pharma
ABIONYX Pharma: Clarification About Clinical Results From the Phase 3 of apoA-I study, CSL112
16.02.2024
·
08:10
Uhr · Business Wire
ABIONYX Pharma Provides an Update on Its Activity, Its Revenue and Its Cash Position for the Third Quarter of 2023
16.11.2023
·
18:00
Uhr · Business Wire
ABIONYX Pharma Completes a Capital Increase in Favor of Categories of Persons
06.10.2023
·
07:30
Uhr · Business Wire
ABIONYX Pharma Announces Its 2023 Half-Year Financial Results
26.09.2023
·
20:00
Uhr · Business Wire
World Sepsis Day September 13, 2023: ABIONYX Pharma Confirms Its Commitment to Sepsis, a Global Public Health Issue
12.09.2023
·
20:14
Uhr · Business Wire
ABIONYX Pharma Provides an Update on Its Business and Cash Position for the First Half of 2023
17.08.2023
·
18:00
Uhr · Business Wire
ABIONYX Pharma Successfully Manufactures a Second Batch of Recombinant Human ApoA-I CER-001 Using a New, Innovative and Robust Industrial Bioprocess
26.07.2023
·
18:30
Uhr · Business Wire
ABIONYX Pharma Announces the Appointment of Laurent Guerci as Chief Digital & Innovation Officer
12.07.2023
·
19:37
Uhr · Business Wire
ABIONYX Pharma Announces a New Compassionate Access Authorization (CAA) for CER-001 in the Rare Disease LCAT Deficiency or Norum Disease in Europe
10.07.2023
·
18:00
Uhr · Business Wire
ABIONYX Pharma Announces Unanimous Approval of All Resolutions Put to the Vote at Its Combined General Meeting
29.06.2023
·
18:00
Uhr · Business Wire
ABIONYX Pharma Provides Further Details on the Setting up of Its Equity-Linked Financing Facility
29.05.2023
·
20:15
Uhr · Business Wire
ABIONYX Pharma Provides an Update on Its Activity and Its Cash Position for the First Quarter 2023
17.05.2023
·
18:30
Uhr · Business Wire
ABIONYX Pharma Announces Its Strategy in Ophthalmology and New Positive Preclinical Results for the Deployment of Two Innovative Technology Platforms: Apotherapy and Biovectorization
31.03.2023
·
18:55
Uhr · Business Wire
ABIONYX Pharma Announces Its 2022 Full-year Financial Results
29.03.2023
·
18:48
Uhr · Business Wire
ABIONYX Pharma Provides an Update on Its Activity and Its Cash Position for the 4th Quarter 2022
28.02.2023
·
18:41
Uhr · Business Wire
ABIONYX Pharma: Press Release
03.02.2023
·
20:44
Uhr · Business Wire
ABIONYX Pharma Announces Its Financial Agenda for the Year 2023
13.01.2023
·
07:30
Uhr · Business Wire
ABIONYX Pharma Provides an Update on Its Business and Cash Position for the First Half Of 2022
18.08.2022
·
17:45
Uhr · Business Wire
ABIONYX Pharma Provides an Update on Its Business and Cash Position for the First Quarter of 2022
19.05.2022
·
18:25
Uhr · Business Wire
ABIONYX Announces Positive Clinical Findings for CER-001 in Treating COVID-19, Published in Biomedecines, Demonstrating That CER-001 Limits Inflammation Effects
24.03.2022
·
18:43
Uhr · Business Wire
ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company’s Share Capital
04.03.2022
·
17:45
Uhr · Business Wire
ABIONYX Pharma Provides an Update on Its Business and Cash Position for Q4 2021
24.02.2022
·
18:00
Uhr · Business Wire
ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company’s Share Capital
07.02.2022
·
18:53
Uhr · Business Wire
ABIONYX Pharma Announces Its Financial Agenda for the Year 2022
31.01.2022
·
17:45
Uhr · Business Wire
ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company’s Share Capital
05.01.2022
·
17:45
Uhr · Business Wire
ABIONYX Pharma Announces That the French Drug Safety Agency (Agence Nationale de Sécurité du Médicament or ANSM) Has Granted a Compassionate Access Authorization for the bio-HDL (CER-001) in COVID-19 Disease
03.01.2022
·
18:00
Uhr · Business Wire
ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company’s Share Capital
06.12.2021
·
18:00
Uhr · Business Wire
ABIONYX Pharma Announces the Completion of a Contribution in Kind to the Company of 100% of the Capital of IRIS Pharma Holding, Fully Compensated by the Issue of New Shares at a Price of €3.60 Per Share to Become a Specialist of Bioproducts...
06.12.2021
·
07:30
Uhr · Business Wire
ABIONYX Announces the Success of Its Capital Increase in Cash by Private Placement at a Price of €3.60 Per Share
02.12.2021
·
07:36
Uhr · Business Wire
ABIONYX Announces the Signing of an Agreement for the Contribution of 100% of the Capital of IRIS Pharma Holding, Fully Remunerated by the Issuance of New ABIONYX Shares at a Fixed Price of 3.60 Euros per Share
17.11.2021
·
19:51
Uhr · Business Wire
ABIONYX Announces New Positive Clinical Results for CER-001 in kidney disease associated with LCAT deficiency Published in The Journal of Internal Medicine
15.11.2021
·
07:30
Uhr · Business Wire
ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company’s Share Capital
08.11.2021
·
19:00
Uhr · Business Wire
ABIONYX Pharma Announces Its Cash Position and Provides an Activity Update for the 3rd Quarter 2021
04.11.2021
·
18:45
Uhr · Business Wire
Werbung ausblenden